Skip to content
Screener

MBX Biosciences, Inc. MBX Q1 2026 earnings

Reported May 7, 2026 · Before market open

EPS-$0.51Beat by $0.11
EPS estimate-$0.62

Next report

Nov 5, 2026 (in 3 months)
EPS estimate-$0.74

Financials

Q1 2026

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.42B+475%
Enterprise value$1.37B+533%

Returns & leverage

See full
Return on equity-25.7%—
Debt / equity0×0.0×
Current ratio30.8×+7.5×

FAQ

When did MBX Biosciences, Inc. report Q1 2026 earnings?
MBX Biosciences, Inc. (MBX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were MBX Biosciences, Inc.'s Q1 2026 revenue and EPS?
MBX Biosciences, Inc. reported eps of $-0.51 for Q1 2026.
Did MBX Biosciences, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.62 by $0.11.
How did MBX Biosciences, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 28.2% from $-0.71.
Where can I find MBX Biosciences, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210825) and the 10-Q periodic report (0001193125-26-210593) directly on SEC EDGAR. The filing index links above go to sec.gov.